Transforming growth factor-1 (TGF-1) is secreted as a latent precursor, consisting of a homodimer of the latency-associated peptide and the mature peptide. TGF-1 can only exert its many functions after going from this latent to an active state, in which the binding site of the mature peptide for its receptor is no longer shielded by the latency-associated peptide. We and others reported that mutations in TGFB1 cause CamuratiEngelmann disease, a rare bone disorder. Until now, seven mutations have been published. In this study, we investigate the effect of the LLL12-13ins, Y81H, R218C, H222D, and C225R mutations on the functioning of TGF-1 in vitro. A luciferase reporter assay specific for TGF--induced transcriptional response with wild type and mutant TGF-1 constructs showed a positive effect of all mutations on TGF-1 activity. By way of enzymelinked immunosorbent assay, we found that in the R218C, H222D, and C225R mutant constructs, this effect is caused by an increase in active TGF-1 in the medium of transfected cells. The LLL12-13ins and Y81H mutations on the contrary have a profound effect on secretion; a decreased amount of TGF-1 is secreted, but the increased luciferase activity shows that the intracellular accumulation of (aberrant) TGF-1 can initiate an enhanced transcriptional response, suggesting the existence of an alternative signaling pathway. Our data indicate that the mutations in the signal peptide and latency-associated peptide facilitate TGF-1 signaling, thus causing Camurati-Engelmann disease.